Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/10/2026, 12:00:00 AM
The U.S. FDA is expected to make an approval decision on orforglipron, Eli Lilly's oral GLP-1 drug for weight loss, by April 10, 2026, expected; medium importance reflects the potential market expansion for obesity treatments.
Korean Translation
미국 식품의약국(FDA)이 일라이 릴리의 경구용 GLP-1 비만 치료제인 올포글리프론에 대한 승인 결정을 2026년 4월 10일까지 내릴 것으로 예상됨.
Related Recent Events
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck is scheduled to release its Q1 2026 financial results before the market opens. Earnings releases typically cause significant price volatility, justifying a Medium importance, scheduled.
4/30/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Other
S&P Global Ratings downgraded Abbott's credit rating to 'A+' from 'AA-' on 2026-03-24 following the completion of the Exact Sciences acquisition, citing increased leverage.
3/24/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Initiated a Phase 1 clinical trial for LX9851, an oral drug candidate for obesity licensed from Lexicon Pharmaceuticals. Analysts estimate a minor positive market reaction, estimated.
3/23/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Eli Lilly announced positive topline results from the TRANSCEND-T2D-1 Phase 3 trial on March 19, 2026, showing its next-generation 'Triple-G' agonist, retatrutide, led to significant reductions in A1C and body weight.
3/19/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
The U.S. FDA approved Wegovy® HD (semaglutide 7.2 mg), a higher dose for weight management, which showed a mean weight loss of 20.7% in trials. Analysts estimate this approval will drive significant revenue growth, and the U.S. launch is expected in April 2026.
3/19/2026, 12:00:00 AM